Figure 1.

FG Treatment Inhibits Tumor Growth in LLC and B16F10 Tumors

(A) LLC tumor growth curves. Treatment with vehicle (Veh) or FG (3 mg; treated on day 10; n = 15).

(B) LLC tumor weight on day 16 (n = 15).

(C) Images of LLC tumors on day 16. Scale bar, 1 cm.

(D) B16F10 tumor growth curves. Treatment with Veh or FG (3 mg; treated on day 10); n = 8.

(E) B16F10 tumor weight on day 16 (n = 8).

(F) Images of B16F10 tumors on day 16. Scale bar, 1 cm.

(G) LLC tumor growth curves. Treatment with Veh (n = 11), FG (3 mg; treated once on day 10; n = 9), or FG twice (3 mg; treated on day 10 and 16; n = 11).

(H) Kaplan-Meier curves showing events-free survival rate of vehicle-, 3 mg FG once-, or 3 mg FG twice-treated mice (n = 10).

(I) Immunofluorescence (IF) images of cleaved caspase-3 (CC3; red)-stained sections of LLC tumors on day 12. Scale bar, 50 μm.

(J) Quantification of the CC3⁺ cell ratio of total cells on day 12 (n = 3).

(K) IF images of Ki-67 (red)-stained sections of LLC tumors on day 12. Scale bar, 50 μm.

(L) Quantification of the Ki-67⁺ cell ratio of total cells on day 12 (n = 3).

Data represent means ±SEM; two-way ANOVA (A, D, and G); Mann-Whitney test (B, E, J, and L); Log rank test (H). ns, not significant; *p < 0.05; **p < 0.01; ****p < 0.0001. See also Figure S1.